The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.
Publication
, Journal Article
Prasit, P; Wang, Z; Brideau, C; Chan, CC; Charleson, S; Cromlish, W; Ethier, D; Evans, JF; Ford-Hutchinson, AW; Gauthier, JY; Gordon, R ...
Published in: Bioorganic & medicinal chemistry letters
July 1999
The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described. It is essentially equipotent to indomethacin both in vitro and in vivo but without the ulcerogenic side effect due to COX-1 inhibition.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Bioorganic & medicinal chemistry letters
DOI
EISSN
1464-3405
ISSN
0960-894X
Publication Date
July 1999
Volume
9
Issue
13
Start / End Page
1773 / 1778
Related Subject Headings
- Sulfones
- Rats
- Prostaglandin-Endoperoxide Synthases
- Membrane Proteins
- Medicinal & Biomolecular Chemistry
- Lactones
- Isoenzymes
- Inhibitory Concentration 50
- Indomethacin
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Prasit, P., Wang, Z., Brideau, C., Chan, C. C., Charleson, S., Cromlish, W., … Zamboni, R. (1999). The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorganic & Medicinal Chemistry Letters, 9(13), 1773–1778. https://doi.org/10.1016/s0960-894x(99)00288-7
Prasit, P., Z. Wang, C. Brideau, C. C. Chan, S. Charleson, W. Cromlish, D. Ethier, et al. “The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.” Bioorganic & Medicinal Chemistry Letters 9, no. 13 (July 1999): 1773–78. https://doi.org/10.1016/s0960-894x(99)00288-7.
Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, et al. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorganic & medicinal chemistry letters. 1999 Jul;9(13):1773–8.
Prasit, P., et al. “The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.” Bioorganic & Medicinal Chemistry Letters, vol. 9, no. 13, July 1999, pp. 1773–78. Epmc, doi:10.1016/s0960-894x(99)00288-7.
Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Léger S, Mancini J, O’Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorganic & medicinal chemistry letters. 1999 Jul;9(13):1773–1778.
Published In
Bioorganic & medicinal chemistry letters
DOI
EISSN
1464-3405
ISSN
0960-894X
Publication Date
July 1999
Volume
9
Issue
13
Start / End Page
1773 / 1778
Related Subject Headings
- Sulfones
- Rats
- Prostaglandin-Endoperoxide Synthases
- Membrane Proteins
- Medicinal & Biomolecular Chemistry
- Lactones
- Isoenzymes
- Inhibitory Concentration 50
- Indomethacin
- Humans